LONG-TERM RHIGF-I TREATMENT IN CHILDREN WITH SHORT STATURE DUE TO GHIS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是评估一种名为重组人胰岛素样生长因子I （rhIGF-I）的实验性药物治疗身材矮小的安全性和有效性。这项研究的目的是观察每天两次注射rhigf - 1是否会改善患有生长激素不敏感综合征的儿童的生长，并测试rhigf - 1的长期安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to evaluate the safety and efficacy of an experimental drug named recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of short stature. The purpose of the study is to see if injections of rhIGF-I two times daily will cause improved growth in children with growth hormone insensitivity syndrome, and to test the long-term safety of rhIGF-I.